Concord Biotech Limited CC-Dec23.pdf · 2024-02-09
Hi, Ankur. Just to pick up on the previous question from the injectable perspective, if you could help us understand. So, I understand the trajectory in terms of first targeting the domestic business, as well as the emerging markets. So, at least if you could help us understand the number of products that we would be sort of targeting for the next one or two year period, plus the therapies that we are looking at. I understand that the adjustable market might be a little bit difficult to give out. But if you could help us understand the range on a broader basis for the domestic market as well as the emerging market, like, overall size of which is $500 million on a global scale basis? Or it could be close to, let's say, a billion dollars, anything from that front.
Look, from an FY '26 perspective, we should be building in the fields of both the injectable formulations as well as the sterile bulk APIs as well.